Abstract Search

ea0070ep340 | Pituitary and Neuroendocrinology | ECE2020

The galant trial: a randomised placebo-controlled trial in patients with a gallium-68 dotatate pet positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size

Boertien Tessel M. , Drent M.L. , Booij Jan , Majoie Charles B.L.M. , Stokkel Marcel P.M. , Hoogmoed Jantien , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Veldman Ronald Groote , Tanck Michael W.T. , Fliers Eric , Bisschop Peter H.

Rationale: At present, there is no approved medical treatment for patients with clinically non-functioning pituitary adenoma. A number of open-label studies suggest that treatment with somatostatin analogues may prevent tumour progression in selected patients. In vivo assessment of somatostatin receptor status using 68Ga-DOTATATE PET could help to select patients responsive to treatment.Trial objective: To investigate the effect of the somatosta...

0 shares

Endocrine Abstracts

The galant trial: a randomised placebo-controlled trial in patients with a gallium-68 dotatate pet positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size

BiosciAbstracts